Announced
Financials
Sources
Tags
Single Bidder
United Kingdom
Private
Biotechnology
Majority
research and development
Cross Border
Friendly
Acquisition
drug discovery
Pending
Synopsis
HitGen, a drug discovery firm, agreed to acquire biotech company Vernalis' research operations from Ligand, a biopharmaceutical company located in San Diego, for $25m. “This is an opportune time to divest the United Kingdom-based operations given our recent acquisitions of four US-based companies that expand our domestic presence and capabilities and fortify our antibody discovery and protein expression businesses. This transaction with HitGen represents an attractive return on our purchase of Vernalis in October 2018, while we maintain economic rights to the promising partnerships that initially attracted us to Vernalis, including with Verona and Corvus," John Higgins, Ligand CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.